YOKNEAM, Israel, October 4, 2017 /PRNewswire/ --
GI innovator Vibrant Ltd. has successfully completed two clinical studies in the US and Israel, to test the efficacy and safety of an innovative intraluminal vibrating capsule for treating chronic idiopathic constipation (CIC). The results will be presented at WCOG 2017 (Orlando, FL, Oct. 13-18).
Vibrant's capsule represents a major departure from existing treatments for constipation. By creating mechanical vibrations that stimulate the colon, the capsule safely and effectively induces motility without the aid of medication, thus improving quality of life for the patient.
The treatment dosage is between 2 to 5 capsules weekly under a physician's supervision.
According to Dr. Eamonn Quigley from Houston Methodist Hospital, "the vibrant capsule offers a new approach to the management of chronic constipation. With less-than-universal response, as well as side effects, current therapies have limited impact - leaving a substantial number of constipation sufferers unsatisfied and uncomfortable. The Vibrant capsule offers a novel, non-chemical treatment that stimulates the normal peristaltic response."
Says Vibrant CEO Lior Ben-Tsur: "We're currently recruiting locations for an additional clinical study in the US. We see potential in treating other constipation disorders, including not only CIC, but also Irritable Bowel Syndrome with Constipation (IBS-C), and Opioid-Induced Constipation (OIC)."
Vibrant has developed a chemical-free, side-effect-free, orally administered vibrating capsule that treats chronic constipation by mechanically stimulating bowel movement. This innovation may aid multiple types of constipation.
Contact: Hagit Taubman
SOURCE GI innovator Vibrant Ltd.